Compare Nano Dimension Ltd - ADR (NNDM) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nano Dimension Ltd - ADR vs Novartis AG — how do they compare? Nano Dimension Ltd - ADR trades at $1.67 (market cap $350.49M), while Novartis AG trades at $152.33 (market cap $295.37B). The key difference: Novartis AG is far larger — about 842.7× Nano Dimension Ltd - ADR's market cap, and Novartis AG pays a 3.07% dividend while Nano Dimension Ltd - ADR pays none. Which is the better fit depends on your goals.
| NNDM | NVS | |
|---|---|---|
Market Cap | $350.49M | $295.37B |
Sector | Technology | Health |
52-Week High | $2.14 | $168.62 |
52-Week Low | $1.21 | $119.31 |
Enterprise Value | -$54.35M | $336.69B |
Dividend Yield | — | 3.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NNDM trades at $1.67, up 2.45% today, with a bullish technical signal from moving averages but overbought RSI levels. The company reported Q2 2026 revenue of $121 million with a net loss of $163 million, reflecting a negative net margin of -135.18%. Recent strategic actions include selling non-core assets to reduce cash burn and appointing an interim CEO amid board restructuring.
The outlook remains challenged by persistent losses and high cash burn, though asset sales may improve liquidity. Investment opportunity hinges on successful execution of cost-saving initiatives and strategic refocusing. Key risks include ongoing operational losses, leadership transitions, and competitive pressures in the additive manufacturing sector.
Novartis AG (NVS) trades at $152.54, down 2.71% on the day, with a neutral technical signal. The company reported strong Q2 2026 earnings, beating EPS estimates of $2.17 with $2.41 actual, driven by oncology drug performance. Revenue for 2025 was $56.67 billion with a net income margin of 22.5%. Analyst consensus is mixed with 24% buy, 68% hold, and 8% sell ratings among 25 analysts.
The outlook is cautiously optimistic, supported by a robust drug pipeline and recent earnings strength, but risks include generic competition pressure on key drugs like Entresto and rising debt levels. The stock presents a stable investment opportunity with solid profitability, though growth may be tempered by industry headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nano Dimension Ltd - ADR
Nano Dimension Ltd is engaged in research and development of a three-dimensional printer that prints electronic circuit boards, also known as printed circuit boards, and ink materials and products based on nanotechnology. Its products consist of two main product lines - Dragonfly 2020 3D printer and proprietary ink products. The company's Dragonfly 2020 3D printer currently in development uses proprietary ink and integrated software to quickly create fully functioning PCB prototypes. Geographically, it generates maximum revenue from the USA followed by the Asia Pacific and Europe and Israel. It serves the Commercial, Research and Printing services industries.
Read more on NNDM →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
